| Item Type | Name |
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Academic Article
|
Studies of minimal residual disease in acute lymphocytic leukemia.
|
|
Academic Article
|
Progress in the treatment of adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
|
|
Academic Article
|
Pediatric regimens for adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Preface: acute lymphoblastic leukemia--quo vadis?
|
|
Academic Article
|
Adult acute lymphoblastic leukemia: concepts and strategies.
|
|
Academic Article
|
Children, adolescents, and young adults with leukemia: the empty half of the glass is growing.
|
|
Academic Article
|
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
|
|
Academic Article
|
Adolescents and young adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
|
|
Academic Article
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
|
Academic Article
|
Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.
|
|
Academic Article
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
|
Academic Article
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
|
Academic Article
|
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
|
Academic Article
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
|
Academic Article
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
|
Academic Article
|
RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
|
Academic Article
|
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
|
|
Academic Article
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
|
Academic Article
|
How I treat acute lymphoblastic leukemia in older adolescents and young adults.
|
|
Academic Article
|
Novel drug targets in acute leukemia.
|
|
Academic Article
|
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
|
|
Academic Article
|
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
|
|
Academic Article
|
Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
|
|
Academic Article
|
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.
|
|
Academic Article
|
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
|
|
Academic Article
|
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).
|
|
Academic Article
|
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
|
|
Academic Article
|
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
|
|
Academic Article
|
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
|
|
Academic Article
|
The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?
|
|
Academic Article
|
Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.
|
|
Academic Article
|
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
|
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
|
Academic Article
|
Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach.
|
|
Academic Article
|
Progress in adult ALL: incorporation of new agents to frontline treatment.
|
|
Academic Article
|
Should immunologic strategies be incorporated into frontline ALL therapy?
|
|
Academic Article
|
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
|
|
Academic Article
|
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
|
|
Academic Article
|
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.
|
|
Academic Article
|
Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
|
Academic Article
|
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.
|
|
Academic Article
|
Management of acute lymphoblastic leukemia in young adults.
|
|
Academic Article
|
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
|
|
Academic Article
|
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
|
|
Academic Article
|
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
|
|
Academic Article
|
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
|
|
Academic Article
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
|
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
|
|
Academic Article
|
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
|
Academic Article
|
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
|
|
Academic Article
|
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
|
|
Academic Article
|
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
|
|
Academic Article
|
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
|
|
Academic Article
|
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.
|
|
Academic Article
|
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
|
|
Academic Article
|
Thrombosis in ALL: a risk without clear mitigation.
|
|
Academic Article
|
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
|
|
Academic Article
|
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
|
|
Academic Article
|
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.
|
|
Academic Article
|
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
|
|
Academic Article
|
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
|
|
Academic Article
|
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
|
|
Academic Article
|
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
|
|
Academic Article
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
|
Academic Article
|
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
|
Academic Article
|
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
|
|
Academic Article
|
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
|
|
Academic Article
|
SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
|
|
Academic Article
|
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
|
|
Academic Article
|
Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
|
|
Academic Article
|
Acute lymphoblastic leukemia displays a distinct highly methylated genome.
|
|
Academic Article
|
Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
|
|
Academic Article
|
Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
|
|
Academic Article
|
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.
|
|
Academic Article
|
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.
|
|
Academic Article
|
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults.
|
|
Academic Article
|
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
|
|
Academic Article
|
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
|
|
Academic Article
|
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
|
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
|
|
Academic Article
|
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures.
|
|
Academic Article
|
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia.
|
|
Academic Article
|
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America.
|
|
Academic Article
|
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
|
|
Academic Article
|
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces.
|
|
Academic Article
|
Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.
|
|
Academic Article
|
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
|
|
Academic Article
|
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
|
|
Academic Article
|
SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
|
|
Academic Article
|
Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators.
|
|
Academic Article
|
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
|
|
Academic Article
|
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
|
|
Academic Article
|
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
|
|
Academic Article
|
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
|
|
Academic Article
|
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
|